title: Brentuximab vedotin.
abstract: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30(+) malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Ansell
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy; D051379:Mice; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin